Day: April 9, 2024

CableLabs North will advance 5G and 10G network research to bring customers seamless connectivity and drive innovation CALGARY, Alberta, April 09, 2024 (GLOBE NEWSWIRE) — Rogers Communications today announced it is collaborating with CableLabs to bring the world’s best technology to Canadians. Located in Calgary at Rogers Barlow campus, CableLabs will be deepening its expertise in Canada through “CableLabs North,” bringing together global industry partners and Rogers technologists to collaborate on network technology solutions. Together, the teams will develop new innovative applications and provide customers seamless connections in and out of the home or workplace. “As the largest operator of coast-to-coast wireless and wireline networks in Canada, we are proud to invest in research and bring the next frontier of networks to Canadians,”...

  NON-REGULATORY PRESS RELEASE Oslo, April 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company will host a webcast on April 17, 2024, at 11:00. Ultimovacs’ management will provide a company update emphasizing recent developments and the future potential within the clinical program. The presentation will be followed by a Q&A session. Date: Wednesday, April 17, 2024 Time: 11:00 (CET) Link to webcast: https://channel.royalcast.com/landingpage/hegnarmedia/20240417_1/ The webcast can be accessed live or as a replay. Questions to the management can be sent in advance to ir@ultimovacs.com or during the webcast. ==ENDS== About Ultimovacs Ultimovacs is a clinical-stage...

LAS VEGAS, NV, April 09, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Hemp, Inc. (OTC: HEMP), a leader in the industrial hemp sector, is pleased to report on a significant development in cannabis biotechnology – the USDA’s approval of a genetically modified (GMO) hemp strain, a testament to the advancements and potential within this burgeoning industry.  The newly approved GMO hemp variety, a breakthrough by the University of Wisconsin, is known as “Badger G”. Unlike traditional breeding methods that rely on the selection and crossbreeding of plants with natural genetic variations, “Badger G” has been crafted through precise genetic editing to amplify certain desirable traits – in this case, the cannabinoid CBG – while eliminating THC and CBD production. Hemp, Inc. recognizes the pivotal role of...

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients. Encouraging VAXINIA efficacy, including a complete response (CR) and two partial responses (PRs), has warranted cohort expansions in biliary tract cancer and other tumour types. Compared to chemotherapy alone, vaccination with HER-Vaxx was associated with a 40% overall survival benefit. HER-Vaxx induced HER2-specific antibody levels correlate with tumour reduction.SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) — Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in...

Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor Activity NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California. “These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. “We now clearly see that used together, IO102-IO103 create an environment in and around the tumor that allow for enhanced anti-tumor activity, at...

– Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone – – Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting – – Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 – CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical...

– Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status – Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease – Confirmed ORR of 22.2% in subset of patients with HPV+ disease – Median duration of treatment in responders was 19.6 months at the time of data cutoff SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) —  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the...

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of the tumor by CD8+ T-Cells, which drive the adaptive immune attack on the tumor.Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471. This combination was surprisingly synergistic. The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.By blocking DLL4 and VEGF, CTX-009 may increase the trafficking and penetration of NK Cells into the tumor microenvironment where CTX-471 may augment the activity of these cells. This activity against the tumor does not require MHC-I integrity.The combination of CTX-009...